Why the study?
Does pathologic sympathetic activation (norepinephrine > 300 pg/mL) predict adverse outcomes in patients with first brain infarction?
Does pathologic sympathetic activation (norepinephrine > 300 pg/mL) predict adverse outcomes in patients with first brain infarction?
Pathologic sympathetic activation, indicated by elevated initial norepinephrine, is an independent predictor of poor functional outcome and increased cardiovascular/cerebrovascular events at 1 year after first brain infarction.
No takes yet. Share an insight, caveat, or question.
Elevated norepinephrine may aid post-stroke risk stratification; leaves open whether targeting sympathetic activation improves outcomes.
Sander et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: